Explain this page
Arphra AIPlain-English read on Revvity, Inc.’s valuationUpcoming events
Next ex-div
Jul 17, 2026in 4w
$0.07
06-09today
- Revvity, Inc. (RVTY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript12d
- Why Is Revvity (RVTY) Up 2% Since Last Earnings Report?17d
- Revvity, Inc. (RVTY) Presents at Bank of America Global Healthcare Conference 2026 Transcript39d
- Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution39d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$105.15
+5.15% vs spot
Recommendation
Hold
18 of 19 methods
Method spread
2bull13bear
±5% threshold
Analyst PT consensus: $111.86 (+11.86%)
Candlestick · 1Y
Open in chart workstation →RVTY
100.00+5.32%H 118.30L 81.22MA50 95.49MA200 95.53Avg vol 1.3M
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.23% | -1.02% | +4.84% | +16.36% | +3.91% | +3.36% | +5.32% | -13.28% | -34.40% | +88.93% | +2921.15% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$2.55M
10 txns
Net flow
−$2.55M
Aftermarket
LiveLast trade
$100.00
102 sh
Bid
$94.00
10 sh
Ask
$108.73
100 sh
Spread
$14.730
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 Dec 2025 | $772.06M | $98.36M | $0.87 |
| Q3 Sep 2025 | $698.95M | $46.65M | $0.40 |
| Q2 Jun 2025 | $720.28M | $55.22M | $0.47 |
| Q1 Mar 2025 | $664.76M | $41.44M | $0.34 |
| Q4 Dec 2024 | $729.37M | $95.04M | $0.78 |
| Q3 Sep 2024 | $684.05M | $93.97M | $0.76 |
Analyst view
DB · price_targets + analyst_gradesConsensus target
$111.86
+11.86% upside
Low
$95.00
Median
$107.00
High
$129.00
Recent actions
0 ↑0 ↓8 hold
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
- Dec 01, 2025
News
DB · news_items- Revvity, Inc. (RVTY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.com·Jun 09, 2026
- Why Is Revvity (RVTY) Up 2% Since Last Earnings Report?zacks.com·Jun 04, 2026
- Revvity, Inc. (RVTY) Presents at Bank of America Global Healthcare Conference 2026 Transcriptseekingalpha.com·May 13, 2026
- Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solutionbusinesswire.com·May 13, 2026
- Revvity to Report Q1 Earnings: What's in Store for the Stock?zacks.com·May 04, 2026
Peers
- EXASExact Sciences Corporation$104.91$20.03B
- ALGNAlign Technology, Inc.$178.91$12.81B
- SOLVSolventum Corporation$66.63$11.56B
- GHGuardant Health, Inc.$87.60$11.49B
- RDYDr. Reddy's Laboratories Limited$13.72$11.42B
- ENSGThe Ensign Group, Inc.$183.72$10.73B
- ICLRICON Public Limited Company$112.85$8.62B
- CRLCharles River Laboratories International, Inc.$165.78$8.18B
Total assets
$12.17B
Total debt
$3.52B
Cash & equiv
$919.87M
Operating CF
$581.78M
Free cash flow
$508.26M
Buybacks
-$820.82M
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Gonzales Anita officer: Vice President and CAO | Sell | 80 | $7.42K | Apr 20, 2026 |
Victor Miriame officer: Please See Remarks | Sell | 1,862 | $180.86K | Feb 24, 2026 |
McMurry-Heath Michelle director | Sell | 600 | $58.36K | Feb 23, 2026 |
Singh Prahlad R. director, officer: Please See Remarks | Sell | 7,885 | $793.47K | Feb 05, 2026 |
Goldberg Joel S officer: Please See Remarks | Sell | 3,544 | $356.17K | Feb 05, 2026 |
Goldberg Joel S officer: Please See Remarks | Sell | 2,217 | $224.65K | Feb 05, 2026 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $2.86B | $356.64M | $241.68M | $2.08 | +8.46% |
| FY 2024 | $2.76B | $410.52M | $295.83M | $2.41 | +10.74% |
| FY 2023 | $2.75B | $399.49M | -$118.38M | $-0.95 | -4.30% |
| FY 2022 | $3.31B | $781.12M | $569.18M | $4.50 | +17.19% |
| FY 2021 | $3.83B | $1.34B | $943.16M | $8.08 | +24.64% |